China’s life science industry is growing quickly, and most experts in the prediction industry place the rate of growth at about 20%, a very healthy number. IMS Health, a global pharmaceutical consultancy, expects slightly better results for China: 22% compound annual growth rate during 2010-2013. That compares to a 4% to 6% rate in the global market. In fact, IMS Health thinks China will be responsible for 21% of all growth in the global pharmaceutical market in the next four years. More details...

Stock Symbol: (NYSE: RX)